Cancers, Free Full-Text

Por um escritor misterioso

Last updated 11 junho 2024

Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6 (HDAC6) in various pathologies, including cancer. This protein effectively intervenes in cellular activities by its primarily cytoplasmic localization. In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML.

Cancer in Lymph Nodes May Help Tumors Metastasize - NCI

Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization

Radical causes of cancer

Detection of HPV-16 DNA by PCR in histologically cancer free lymph nodes from patients with cervical cancer. - Abstract - Europe PMC

Cancer Awareness Month Calendar & Ribbon Color

Cancer Cells vs. Normal Cells: How Are They Different?

Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers - European Urology Focus

Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.